Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Keizer

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and XposeR J Keizer, M O Karlsson, A Hooker
Alimentary Pharmacology & Therapeutics|June 27, 2015
Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practiceD J Buurman, J M Maurer, R J Keizer, et al.
Clinical Pharmacokinetics|June 28, 2025
Population Pharmacokinetics Model of Thioguanine in Patients with Inflammatory Bowel DiseaseA B Bayoumy, N K H de Boer, R J Keizer, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 24, 2007
[The pharmacokinetics of monoclonal antibodies]R J Keizer, A D R Huitema, C W N Damen, et al.
Clinical and Translational Science|June 1, 2017
New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment ResponseI H Bartelink, N Zhang, R J Keizer, et al.
Clinical Immunology (Orlando, Fla.)|December 27, 2011
Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safetyJ J Hofstra, I Kleine Budde, E van Twuyver, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
CPT: Pharmacometrics & Systems Pharmacology|July 10, 2013
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and XposeR J Keizer, M O Karlsson, A Hooker
Alimentary Pharmacology & Therapeutics|June 27, 2015
Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practiceD J Buurman, J M Maurer, R J Keizer, et al.
Clinical Pharmacokinetics|June 28, 2025
Population Pharmacokinetics Model of Thioguanine in Patients with Inflammatory Bowel DiseaseA B Bayoumy, N K H de Boer, R J Keizer, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 24, 2007
[The pharmacokinetics of monoclonal antibodies]R J Keizer, A D R Huitema, C W N Damen, et al.
Clinical and Translational Science|June 1, 2017
New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment ResponseI H Bartelink, N Zhang, R J Keizer, et al.
Clinical Immunology (Orlando, Fla.)|December 27, 2011
Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safetyJ J Hofstra, I Kleine Budde, E van Twuyver, et al.
Pageof 1